Gilbert N. Lam is a Pharmacokinetist with more than 30 years of experience in the pharmaceutical industry. As President and Chief Scientific Officer of MicroConstants, he is responsible for overseeing the direction of the company and its overall operations.
Prior to founding MicroConstants in 1998, Gil was the Executive Director of Preclinical Safety and Drug Disposition at CoCensys, a neuropharmaceutical company. During that time, he was responsible for preclinical and clinical pharmacokinetic development programs of new chemical entities proprietary to CoCensys. Gil began his career at DuPont Pharmaceuticals where he supported various discovery and research activities. In 1994, he became the Director of Preclinical Pharmacokinetics and Metabolism at DuPont and was responsible for the development efforts in IND and NDA applications.
Gil received his bachelor’s degree in Pharmaceutical Sciences from the State University of New York (SUNY) at Buffalo and his Ph.D. in Pharmaceutical Sciences from the University of Illinois Medical Center in Chicago, Illinois. He has co-authored more than 40 peer-reviewed publications and is a member of the American Association for Pharmaceutical Scientists (AAPS) and the International Society for the Study of Xenobiotics (ISSX).
David F. Beyerlein has over 15 years of experience managing laboratory operations, is an experienced analytical chemist, and is highly skilled in the use of the mass spectrometer. David co-founded MicroConstants with Dr. Lam in 1998. As the Vice President of Global Operations, he is responsible for overseeing and managing all laboratory operations, project and sample management, information technology, and purchasing.
Prior to co-founding MicroConstants, David was part of the mass spectrometry group at Covance’s facility in Madison, Wisconsin. Before joining Covance, he was a Senior Research and Development Scientist in the Bioanalytical/Mass Spectrometry group at the Madison facility of PPD-Pharmaco where he started their Bioanalytical LC/MS/MS Department. David received his bachelor’s degree in Chemistry from the University of Wisconsin - Eau Claire.
Jose V. Buenviaje has over 20 years of research, analytical, and manufacturing experience in the biotechnology industry and more than 18 years of experience with Quality Assurance Compliance related to cGLP and cGMP regulations. As the Vice President of Quality Assurance and Regulatory Compliance, Jose serves as the executive quality authority in all interactions with Regulatory representatives. He is also responsible for the creation, compliance, and deployment of MicroConstants’ global quality system, including internal GLP policies and procedures consistent with internationally recognized standards.
Prior to joining MicroConstants in 1999, Jose Buenviaje was the Quality Assurance Supervisor at Syntron Bioresearch, a licensed Medical Device Establishment in Carlsbad, California. While at Syntron, Jose implemented, standardized, and supervised the QA Department and participated in the FDA 510K submission for medical devices designed to measure drugs of abuse. Before Syntron, Jose spent five years working in the field of forensic chemistry and has testified as an expert witness in the field of toxicology for numerous cases for the state of California. Jose received his bachelor’s degree in Biology/Psychology from the University of California, San Diego.
Ron Shevock has over 15 years of business development experience with CROs offering contract research services to pharmaceutical and biotech companies at all stages of drug development. He joined MicroConstants in 2009 as Director of Business Development. In this role, Ron is responsible for developing new business opportunities in the Western United States, as well as in international markets.
Before joining MicroConstants, Ron was a Business Development Manager at Frontage Laboratories where he was responsible for building a new sales territory and establishing business opportunities in the Pacific Mountain Region. Prior to that, he was a Business Development Manager responsible for the Western Territory Region at Absorption Systems and an Account Executive in the Late Stage Development Services division at Covance, Inc. He received his bachelor’s degree in Biology from King’s College in Wilkes-Barre, Pennsylvania.
Patricia deLisio has more than 12 years of experience selling contract research services to companies in the pharmaceutical, biotech, agrochemical, animal health, and specialty chemical industries. Pat joined MicroConstants in 2013 as Director of Business Development. In this role, she is responsible for developing new business opportunities in the Eastern United States, as well as in international markets.
Before joining MicroConstants, Pat held business development, program management, and site director positions at MPI Research. Prior to that, Pat spent four years as a GLP Technical and Quality Specialist with RoseTECH Consulting. During that time, she performed data audits for GLP compliance and provided bioanalytical and GLP training to their pharmaceutical and CRO clients. She has also held business development positions at several bioanalytical and toxicology CROs throughout the United States, including Advion, Azopharma, and Ricerca Biosciences.
Pat began her career as a research chemist, has spent 11 years as a Study Director/Principal Investigator, and has extensive experience in HPLC method development and validation for sample analysis supporting regulated toxicology and metabolism studies. Pat received her bachelor’s degree in Chemistry from Notre Dame College in South Euclid, Ohio.
David Johnson has over 13 years of experience implementing and managing preclinical drug discovery contract research services. In 2000, he joined MicroConstants establishing the Drug Metabolism group which is responsible for preclinical drug metabolism research and non-GLP discovery bioanalytical research.
Previously David was the Drug Metabolism Product Development Manager for the Pharmazyme division of Immune Complex Corporation. During that time, he conceived, designed, and developed an in vitro drug metabolism contract research program utilizing recombinant cytochrome P450s and other drug metabolizing enzymes. Prior to Pharmazyme, David was a Research Assistant at Hybritech where he developed methods to automate the radiolabeling of monoclonal antibodies for use in medical diagnostic kits. He received his bachelor’s degree in Chemistry from the University of California, San Diego and his Ph.D. from the University of Minnesota, Twin Cities.
Doinita Serban, Ph.D.
Director, Biomarker Research
Doinita Serban has more than 15 years of experience in the pharmaceutical industry specializing in cancer and vascular biology, immunology, and bioanalysis in preclinical and clinical research. Doinita joined MicroConstants in 2013 as the Director of Biomarker Research. In this role, she is responsible for biomarker analysis, immunoassays, and cell-based assays of proteins, peptides, and oligonucleotides using semi-automated and automated platforms.
Before joining MicroConstants, Doinita was Director of Research at Amaris Biosciences where she supported the development of clinical trial studies of vascular disrupting agents and monoclonal antibodies as therapies for solid and hematological tumors. Prior to Amaris, she was a Senior Scientist at Pfizer where she established biomarkers of colon cancer, melanoma, and inflammation using high-throughput LC/MS/MS, fit-for-purpose assays, and cell-based orthogonal testing integrated onto automated platforms. Doinita began her career with fellowship positions sponsored by the Marie Curie Foundation, Susan G. Komen Breast Cancer Foundation, and the Federation of European Biochemical Societies (FEBS).
Doinita received both her bachelor’s degree in Biology and Biochemistry and master’s degree in Medical Biochemistry from the University of Bucharest in Romania, and her Ph.D. in Cell Biology and Biophysics from the University of Missouri in Kansas City.
Adrienne Griffith has more than 13 years of experience in method development, method validation, and sample analysis. She joined MicroConstants' Bioanalytical Chemistry team in 2000 as a Laboratory Intern while still completing classes for her bachelor's degree. Upon graduation, she accepted a full-time position as an analytical scientist and has since progressed through the Company to become a Manager overseeing the Bioanalytical Chemistry and Metrology (QC) departments. In this role, Adrienne serves as a Principal Investigator for bioanalytical projects and is responsible for corresponding with clients, scheduling sample analysis, and reviewing raw data and reports. She also supervises the day-to-day operations of both departments. Adrienne received her bachelor’s degree in Biology from the University of San Diego in California.
Jeff Hoffman has more than 18 years of experience in the contract research and pharmaceutical industries. He joined MicroConstants in 2004, and currently serves as a Principal Investigator for the Bioanalytical Chemistry and Formulation Analysis departments. In this role, he oversees the day-to-day operations of the Bioanalytical and Formulation departments and offers hands-on leadership in the areas of method validation and analytical sample analysis.
Previously, Jeff was at Dermtech/Pracs Institute where his responsibilities included analytical method development, method validation, and supervision of the transdermal laboratory operations. Prior to that, he was an analytical chemist in the Toxicology Department at PoisonLab. Jeff received his bachelor’s degree in Biology and Zoology from Humboldt State University in Arcata, California.
Lilin Wang has more than 18 years experience in immunological assay and bioassay development, validation, and optimization. He joined MicroConstants in 2011 as the Manager of Immunology. In this role, he serves as a Principal Investigator and is responsible for immunoassay and bioassay development, validation, and sample analysis to support preclinical and clinical studies.
Prior to joining MicroConstants, Lilin consulted for several pharmaceutical and biotech companies. During that time he developed immunological and molecular assays for cancer and autoimmune diseases, performed antibody generation and validation, and developed novel nanoparticle-based immunofluorescence assays. Lilin has also held scientific and leadership positions at Life Technologies and Alliance Pharmaceutical Corp. where he conducted research and development in the areas of immunotherapies and biomarkers.
Lilin earned his bachelor’s degree in Molecular Cell Biology/Immunology and his master’s degree in Immunology from Wuhan University in China. He is an inventor of several patents and the author of peer reviewed scientific publications on topics such as immunology, cancer biology, and infectious diseases.
Michelle Mason joined MicroConstants as an Administrative Assistant in 2002. That same year, she was promoted to become a Project Coordinator responsible for working with clients to coordinate the development of project plans. Michelle is now the Manager of Project Operations and responsible for overseeing day-to-day project operations, implementing strategies to enhance client services, and identifying opportunities to improve efficiency throughout the company. Michelle also manages the Project Management, Sample Management, and Specimen Collection Kit departments. She earned her bachelor’s degree in Psychology from San Diego State University in California.
Mary P. Gil has more than 7 years of experience in quality assurance compliance related to GLP regulations. She joined MicroConstants in 2003 as an Analytical Scientist in the Drug Metabolism group. She spent three years in the lab before transitioning into the Quality Assurance (QA) Department in 2006. In her current role as Quality Assurance Manager, Mary is now responsible for developing, implementing and maintaining regulatory and quality programs to ensure compliance with FDA, OECD and MHLW Good Laboratory Practice (GLP) regulations. She also supervises the day-to-day operations of the Quality Assurance, Document Control and Archive departments and interfaces with clients and external regulatory agencies regarding quality audits or other regulatory requirements. Mary received her bachelor’s degree in Biochemistry and Cell Biology from the University of California, San Diego.
Henry J. Pieniaszek, Ph.D.
Dr. Henry J. Pieniaszek has spent more than 30 years working in the pharmaceutical industry, including 20 years at DuPont Pharmaceuticals Co. (currently Bristol-Myers Squibb Co.). Henry is currently working as a consultant to the pharmaceutical industry and has assisted various clients, including MicroConstants, in their development activities and in gaining marketing approvals. In addition to his consulting work, Henry co-teaches an annual workshop sponsored by the University of Arizona entitled “Principles of Pharmacokinetics and Toxicokinetics for the Industrial Scientist” and has lectured on topics in the areas of pharmacokinetics/pharmacodynamics, clinical pharmacology, bioanalytical method validation, and biomarker development. He also serves as a reviewer for seven pharmaceutical and medical journals and is on the Editorial Board for the Journal of Clinical Pharmacology.
Henry began his career as a Research Scientist at DuPont Pharmaceuticals Co. He eventually went on to become a Senior Director of the Clinical Pharmacokinetics/Pharmacodynamics and Biomarker Development groups at the Company before leaving in 2002. During his 20 years with DuPont, Dr. Pieniaszek was involved with numerous discovery and development projects and assisted in the preclinical and/or clinical development of five novel medicines: Innohep (low molecular weight heparin, 7/00), Sustiva (antiviral for HIV, 9/98), Bianda (anticancer, 2/96), ReVia (treatment of alcohol dependence, 12/94), and Ethmozine (antiarrhythmic, 6/90), which eventually gained marketing approval.
Dr. Pieniaszek received his Ph.D. in Pharmaceutical Sciences from the University of Arizona and his bachelor’s degree in Biology and Chemistry from the State University College of New York in Oswego. In 1991 and 1999, Henry was selected by his peers as a Fellow of the American College of Clinical Pharmacology (ACCP) and the American Association of Pharmaceutical Scientists (AAPS), respectively. He has co-authored more than 50 peer-reviewed publications and 80 published abstracts.